The dual role of complement in the progression of renal disease in NZB/W F 1 mice and alternative pathway inhibition

Molecular Immunology

Volumn 49, Issue 1-2, 2011, Pages 317-323

  Sekine, Hideharu ^a   Ruiz, Phillip ^b   Gilkeson, Gary S ^a   Tomlinson, Stephen ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Complement; Factor H; Kidney; Lupus

Indexed keywords

ALBUMIN; COMPLEMENT; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN; SODIUM CHLORIDE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; EXPERIMENTAL MODEL; FEMALE; GLOMERULONEPHRITIS; KIDNEY; KIDNEY DISEASE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LUPUS NEPHRITIS; MICE; MICE, INBRED NZB;

MUS;

EID: 82455209021     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.09.015     Document Type: Article

References (30)

1. Atkinson C., Qiao F., Song H., Gilkeson G.S., Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J. Immunol. 2008, 180:1231-1238.
2. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., Tsokos G.C., Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 2005, 115:2444-2453.
3. Bao L., Quigg R.J. Complement in lupus nephritis: the good, the bad, and the unknown. Semin. Nephrol. 2007, 27:69-80.
4. Boackle S.A., Culhane K.K., Brown J.M., Haas M., Bao L., Quigg R.J., Holers V.M. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity 2004, 37:111-123.
5. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19:56-59.
6. Botto M., Walport M.J. Hereditary deficiency of C3 in animals and humans. Int. Rev. Immunol. 1993, 10:37-50.
7. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J. Autoimmun. 2010, 34:J276-J286.
8. Clynes R., Dumitru C., Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
9. Einav S., Pozdnyakova O.O., Ma M., Carroll M.C. Complement C4 is protective for lupus disease independent of C3. J. Immunol. 2002, 168:1036-1041.
10. Elliott M.K., Jarmi T., Ruiz P., Xu Y., Holers V.M., Gilkeson G.S. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004, 65:129-138.
11. Holers V.M., Boackle S.A. Complement receptor 2 and autoimmunity. Curr. Dir. Autoimmun. 2004, 7:33-48.
12. Hron J.D., Peng S.L. Type I IFN protects against murine lupus. J. Immunol. 2004, 173:2134-2142.
13. Huang Y., Qiao F., Atkinson C., Holers V.M., Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 2008, 181:8068-8076.
14. Kovacs J.M., Hannan J.P., Eisenmesser E.Z., Holers V.M. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J. Biol. Chem. 2010, 285:27251-27258.
15. Manderson A.P., Botto M., Walport M.J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 2004, 22:431-456.
16. Matsumoto K., Watanabe N., Akikusa B., Kurasawa K., Matsumura R., Saito Y., Iwamoto I., Saito T. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum. 2003, 48:486-494.
17. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black×New Zealand White) F1 but not in BALB/c mice. J. Immunol. 2005, 174:2499-2506.
18. Mitchell D.A., Pickering M.C., Warren J., Fossati-Jimack L., Cortes-Hernandez J., Cook H.T., Botto M., Walport M.J. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J. Immunol. 2002, 168:2538-2543.
19. Pickering M.C., Botto M., Taylor P.R., Lachmann P.J., Walport M.J. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 2000, 76:227-324.
20. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., Carroll M.C. A critical role for complement in maintenance of self-tolerance. Immunity 1998, 9:721-731.
21. Quigg R.A., Kozono Y., Berthiaume D., Lim A., Salant J., Weinfeld A., Griffin P., Kremmer E., Holers V.M. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 1998, 160:4553-4560.
22. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003, 197:777-788.
23. Sekine H., Graham K.L., Zhao S., Elliott M.K., Ruiz P., Utz P.J., Gilkeson G.S. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J. Immunol. 2006, 177:7423-7434.
24. Sekine H., Kinser T.T., Qiao F., Martinez E., Paulling E., Ruiz P., Gilkeson G.S., Tomlinson S. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011, 63:1076-1085.
25. Sekine H., Reilly C.M., Molano I.D., Garnier G., Circolo A., Ruiz P., Holers V.M., Boackle S.A., Gilkeson G.S. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J. Immunol. 2001, 166:6444-6451.
26. Stott D.I., McLearie J., Neilson L. Analysis of the clonal origins of autoantibodies against thyroglobulin and DNA in autoimmune thyroiditis and systemic lupus erythematosus. Clin. Exp. Immunol. 1986, 65:520-533.
27. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
28. Watanabe H., Garnier G., Circolo A., Wetsel R.A., Ruiz P., Holers V.M., Boackle S.A., Colten H.R., Gilkeson G.S. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J. Immunol. 2000, 164:786-794.
29. Whaley K. Complement and immune complex diseases. Complement in Health and Disease 1987, 163-183. MTP Press, Norwell, MA. K. Whaley (Ed.).
30. Wu X., Jiang N., Deppong C., Singh J., Dolecki G., Mao D., Morel L., Molina H.D. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J. Immunol. 2002, 169:1587-1592.